Brokerages expect BIO-TECHNE Corp (NASDAQ:TECH) to announce earnings of $1.15 per share for the current fiscal quarter, according to Zacks. Six analysts have made estimates for BIO-TECHNE’s earnings, with estimates ranging from $1.05 to $1.21. BIO-TECHNE reported earnings per share of $0.97 in the same quarter last year, which would indicate a positive year over year growth rate of 18.6%. The business is expected to report its next quarterly earnings results on Tuesday, May 1st.

On average, analysts expect that BIO-TECHNE will report full year earnings of $4.33 per share for the current financial year, with EPS estimates ranging from $4.07 to $4.51. For the next fiscal year, analysts expect that the business will post earnings of $4.91 per share, with EPS estimates ranging from $4.52 to $5.15. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover BIO-TECHNE.

BIO-TECHNE (NASDAQ:TECH) last posted its earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.10. The firm had revenue of $154.15 million for the quarter, compared to analyst estimates of $145.93 million. BIO-TECHNE had a return on equity of 14.39% and a net margin of 19.17%. The company’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.81 earnings per share.

TECH has been the topic of a number of recent analyst reports. BidaskClub raised BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a research report on Friday. Deutsche Bank set a $163.00 target price on BIO-TECHNE and gave the company a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research upgraded BIO-TECHNE from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a research note on Saturday, February 10th. Craig Hallum restated a “buy” rating and set a $160.00 target price (up from $140.00) on shares of BIO-TECHNE in a research note on Wednesday, February 7th. Finally, Robert W. Baird upped their target price on BIO-TECHNE from $154.00 to $157.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $148.60.

BIO-TECHNE (TECH) traded up $1.64 during trading hours on Friday, hitting $148.18. The company had a trading volume of 324,942 shares, compared to its average volume of 187,524. The company has a current ratio of 3.10, a quick ratio of 2.49 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $5,501.93, a P/E ratio of 48.58, a P/E/G ratio of 2.81 and a beta of 0.75. BIO-TECHNE has a twelve month low of $98.22 and a twelve month high of $148.87.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 2nd. Shareholders of record on Friday, February 16th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, February 15th. This represents a $1.28 dividend on an annualized basis and a yield of 0.86%. BIO-TECHNE’s payout ratio is currently 41.97%.

In other BIO-TECHNE news, Director Charles A. Dinarello sold 5,000 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total transaction of $680,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB bought a new position in shares of BIO-TECHNE during the 4th quarter worth about $445,000. APCM Wealth Management for Individuals bought a new position in shares of BIO-TECHNE during the 4th quarter worth about $259,000. MetLife Investment Advisors LLC bought a new position in shares of BIO-TECHNE during the 4th quarter worth about $3,071,000. Vident Investment Advisory LLC boosted its position in shares of BIO-TECHNE by 78.4% during the 4th quarter. Vident Investment Advisory LLC now owns 7,235 shares of the biotechnology company’s stock worth $937,000 after purchasing an additional 3,180 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of BIO-TECHNE by 17.5% during the 4th quarter. Jane Street Group LLC now owns 3,016 shares of the biotechnology company’s stock worth $391,000 after purchasing an additional 449 shares in the last quarter. 97.15% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate BIO-TECHNE Corp (TECH) to Post $1.15 EPS” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/03/16/zacks-brokerages-anticipate-bio-techne-corp-tech-to-post-1-15-eps.html.

BIO-TECHNE Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Get a free copy of the Zacks research report on BIO-TECHNE (TECH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.